Piper Sandler analyst David Westenberg lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.65 from $2.40 and keeps a Neutral rating on the shares following quarterly results. The firm cites lower expected capital expenditures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion
- Tikvah intends to vote against Quanterix’s proposed merger with Akoya
- Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens
- Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance
- Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges